ADPT News and Press, Adaptive Biotechnologies Corporation From 05/07/24

2024-05-07 16:46:31 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: A Post Earnings Assessment Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript Adaptive Biotechnologies Corporation 2023 Q4 - Results - Earnings Call Presentati...

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-05-06 17:35:57 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: A Post Earnings Assessment Adaptive Biotechnologies announces conclusion of strategic review, expects Q1 revenue between $41M and $43M Adaptive Biotechnologies GAAP EPS of -$0.48 misses...

SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financia...

2024-04-02 16:21:13 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: A Post Earnings Assessment Adaptive Biotechnologies GAAP EPS of -$0.48 misses by $0.15, revenue of $45.78M misses by $2.68M Adaptive Biotechnologies Q4 2023 Earnings Preview R...

SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, incl...

SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will host a business...

2024-02-25 11:41:00 ET Summary Today, we circle back on diagnostic concern Adaptive Biotechnologies Corporation, which recently posted its fourth quarter results. The company develops immune medicine platforms for the diagnosis and treatment of diseases, with its core growth drive...

2024-02-25 10:40:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the fourth quarter of 2023, Aristo...